TABLE 1.

HGF/c-Met signaling inhibitors in preclinical studies.

Cancer	Agent	Cell lines	Primary results	References
Hepatocellular carcinoma	Cabozantinib	MHCC97H	Cabozantinib inhibited tumor growth by decreasing angiogenesis, inhibiting proliferation, and promoting apoptosis	Xiang et al., 2014
Gastric cancer	Savolitinib	Hs746t	Volitinib displayed a highly selective profile across a gastric cell line panel, potently inhibiting cell growth only in those lines with dysregulated c-Met	Gavine et al., 2015
Pancreatic cancer	Crizotinib	Suit-2	Crizotinib inhibits the peritoneal dissemination of Suit-2 cells	Takiguchi et al., 2017
	Crizotinib + gemcitabine	Orthotopic PDAC-FM-GC mouse models	Crizotinib decreased tumor dimension, prolonged survival, and increased blood and tissue concentrations of gemcitabine	Avan et al., 2013
Melanoma	SU11274	Human malignant melanoma cell lines A375 (ATCC CRL-1619), M14 and M4Beu	SU11274 substantially decreased number of cells in adherent and spheroid cultures, but increased their tumorigenic potential	Kucerova et al., 2016